Vanda Pharmaceuticals Inc. (VNDA)

18.46
0.24 1.30
NASDAQ : Health Technology
Prev Close 18.22
Open 18.28
Day Low/High 18.25 / 18.60
52 Wk Low/High 13.88 / 33.44
Volume 166.50K
Avg Volume 933.20K
Exchange NASDAQ
Shares Outstanding 52.64M
Market Cap 962.84M
EPS 0.50
P/E Ratio 38.10
Div & Yield N.A. (N.A)

Latest News

Vanda Pharmaceuticals To Present At The Cowen And Company 39th Annual Health Care Conference

Vanda Pharmaceuticals To Present At The Cowen And Company 39th Annual Health Care Conference

WASHINGTON, March 7, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts on Monday,...

(VNDA) Alert: Johnson Fistel Reminds Investors Of Deadline In The Class Action Lawsuit Against Vanda Pharmaceuticals Inc.

(VNDA) Alert: Johnson Fistel Reminds Investors Of Deadline In The Class Action Lawsuit Against Vanda Pharmaceuticals Inc.

SAN DIEGO, March 7, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP reminds investors that a class action lawsuit has been filed against Vanda Pharmaceuticals Inc.

Relative Strength Alert For Vanda Pharmaceuticals

Relative Strength Alert For Vanda Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

VNDA INVESTOR ALERT: Rosen Law Firm Reminds Vanda Pharmaceuticals Inc. Investors Of Important Deadline In First-Filed Case - VNDA

VNDA INVESTOR ALERT: Rosen Law Firm Reminds Vanda Pharmaceuticals Inc. Investors Of Important Deadline In First-Filed Case - VNDA

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Vanda Pharmaceuticals Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces The Filing Of A Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces The Filing Of A Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Vanda Pharmaceuticals Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Vanda Pharmaceuticals Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Vanda Pharmaceuticals Inc.

Vanda (VNDA) Class Action Lawsuit: Bernstein Liebhard LLP Announces A Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. - VNDA

Vanda (VNDA) Class Action Lawsuit: Bernstein Liebhard LLP Announces A Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. - VNDA

NEW YORK, Feb. 27, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Vanda...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Vanda Pharmaceuticals Inc. - VNDA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK, Feb. 26, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Vanda Pharmaceuticals, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Vanda Pharmaceuticals, Inc.

Federman & Sherwood announces that on February 25, 2019, a class action lawsuit was filed in the United States District Court for the Eastern District of New York against Vanda Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. - VNDA

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. - VNDA

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Vanda Pharmaceuticals Inc.

VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm

VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vanda Pharmaceuticals Inc.

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Vanda Pharmaceuticals Inc. Investors

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Vanda Pharmaceuticals Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Vanda Pharmaceuticals Inc.

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Vanda Pharmaceuticals Inc. Investors

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Vanda Pharmaceuticals Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reports Fourth Quarter 2018 And Full Year 2018 Financial Results

Vanda Pharmaceuticals Reports Fourth Quarter 2018 And Full Year 2018 Financial Results

- Full year 2018 total revenues grew to $193.1 million, a 17% increase compared to 2017

VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm

VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm

NEW YORK, Feb. 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vanda Pharmaceuticals Inc.

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Vanda Pharmaceuticals Inc.

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Vanda Pharmaceuticals Inc.

NEW YORK, Feb. 12, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Vanda Pharmaceuticals Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Vanda Pharmaceuticals Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Vanda Pharmaceuticals Inc.

The law firm of Kirby McInerney LLP is investigating potential claims against Vanda Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Vanda Pharmaceuticals Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Vanda Pharmaceuticals Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Vanda Pharmaceuticals Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DHX, EWBC, KE, MSON, OMN, RDWR, RNR, SEE Downgrades: AR, FTAI, K, RYN, SNY, TWO, VNDA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Vanda Pharmaceuticals Takes A Stand Against Unnecessary Animal Research

Vanda Pharmaceuticals Takes A Stand Against Unnecessary Animal Research

Company pursuing legal action against the FDA for requiring unnecessary studies that would result in the death of dozens of dogs without legal authority.

First Week Of February 15th Options Trading For Vanda Pharmaceuticals (VNDA)

First Week Of February 15th Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

FDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application For Review In The Treatment Of Jet Lag Disorder

FDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application For Review In The Treatment Of Jet Lag Disorder

WASHINGTON, Dec. 20, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Announces Positive Pivotal Study Results For HETLIOZ® (tasimelteon) In Patients With Smith-Magenis Syndrome

Vanda Announces Positive Pivotal Study Results For HETLIOZ® (tasimelteon) In Patients With Smith-Magenis Syndrome

WASHINGTON, Dec. 10, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reaches Analyst Target Price

Vanda Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Vanda Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $29.40, changing hands for $31.47/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Vanda Announces Positive Phase II Study Results For Tradipitant In Patients With Gastroparesis

Vanda Announces Positive Phase II Study Results For Tradipitant In Patients With Gastroparesis

Management to host conference call on Monday, December 3 at 8:30 AM ET

TheStreet Quant Rating: C+ (Hold)